Showing results (131-140 of 1,297) with videos related to

Sort By:
Pageof 130
Journal of the American Society of Nephrology : JASN|April 28, 2012
Corticosteroid therapy in IgA nephropathyJicheng Lv, Damin Xu, Vlado Perkovic, et al.
Nephrology (Carlton, Vic.)|August 31, 2016
Effects of health service geographic accessibility in patients with treated end stage kidney disease: Cohort study 2000-2010Sradha Kotwal, Martin Gallagher, Alan Cass, et al.
JMIR Research Protocols|June 18, 2015
Rural Versus Urban Health Service Utilization and Outcomes for Renal Patients in New South Wales: Protocol for a Data Linkage StudySradha Kotwal, Angela Webster, Alan Cass, et al.
Nephrology (Carlton, Vic.)|July 9, 2010
Applying evidence into routine clinical care at a unit level: the exemplar of renal anaemia managementMartin P Gallagher, Alan Cass, Jonathan C Craig
Diabetes Care|August 5, 2009
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trialSophia Zoungas, Bastiaan E de Galan, Toshiharu Ninomiya, et al.
Journal of the American Society of Nephrology : JASN|February 20, 2009
Lowering blood pressure reduces renal events in type 2 diabetesBastiaan E de Galan, Vlado Perkovic, Toshiharu Ninomiya, et al.
Kidney International|December 14, 2012
Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitusMuh Geot Wong, Vlado Perkovic, Mark Woodward, et al.
BMJ Global Health|January 26, 2022
Prevalence of chronic kidney disease in Asia: a systematic review and analysisThaminda Liyanage, Tadashi Toyama, Carinna Hockham, et al.
Journal of Cardiac Failure|March 1, 2026
SGLT2 inhibition in Patients with Type 2 Diabetes and CKD Experiencing a Deterioration in Estimated Glomerular Filtration Rate to 2Safia Chatur, Robert A Fletcher, Emily Yeung, et al.
Nephrology (Carlton, Vic.)|May 13, 2016
Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialJoel Gummer, Robert Trengove, Elaine M Pascoe, et al.
Pageof 130